Phibro Animal Health (NASDAQ:PAHC) Raised to “Overweight” at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a neutral rating to an overweight rating in a research note issued to investors on Monday, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has $35.00 target price on the stock, up from their prior target price of $25.00.

Other analysts also recently issued reports about the company. Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the stock an “equal weight” rating in a report on Wednesday, June 25th. Wall Street Zen raised Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. BNP Paribas raised Phibro Animal Health to a “hold” rating in a report on Monday, June 16th. Finally, BNP Paribas Exane upgraded shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price target on the stock in a research note on Monday, June 16th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.40.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $31.39 on Monday. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $31.53. The stock has a market capitalization of $1.27 billion, a PE ratio of 40.24, a PEG ratio of 0.50 and a beta of 0.75. The company has a debt-to-equity ratio of 2.67, a quick ratio of 1.23 and a current ratio of 2.91. The stock has a 50-day simple moving average of $24.06 and a 200-day simple moving average of $22.25.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.11. The company had revenue of $347.80 million for the quarter, compared to the consensus estimate of $352.41 million. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. On average, analysts predict that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Wednesday, June 4th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, June 4th. This represents a $0.48 annualized dividend and a dividend yield of 1.53%. Phibro Animal Health’s dividend payout ratio (DPR) is 61.54%.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors have recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new stake in Phibro Animal Health during the 1st quarter worth approximately $10,312,000. Invesco Ltd. raised its stake in shares of Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock worth $8,282,000 after purchasing an additional 186,087 shares during the last quarter. Axecap Investments LLC acquired a new stake in shares of Phibro Animal Health during the first quarter worth $3,696,000. Millennium Management LLC grew its position in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after buying an additional 154,281 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in Phibro Animal Health by 56.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 301,173 shares of the company’s stock valued at $6,325,000 after buying an additional 108,918 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.